Kornimate/medical-research-clean huggingface dataset:
liposomal doxorubicin (lipo-dox) in patients with brain metastasis from breast cancer

Conditions: Breast Cancer

Summary: primary objective: to determine the brain response rate of lipo-dox in breast cancer patients with brain metastasis secondary objectives: 1. to determine the overall objective response rate (orr) 2. to determine the progression free survival, and duration of objective response 3. to evaluate the overall survival (os) 4. to assess the safety profiles

this is an open-label, non-comparative phase ii clinical trial. approximately thirty-three patients will be enrolled in order to obtain twenty-nine evaluable subjects who received two cycles of study treatment in simon's 2-stage optimal design. duration of subject involvement: study treatment should be administered up to disease progression, intolerable toxicity, or consent withdrawal. recruitment period: 10 months

Eligibility criteria:
inclusion criteria: * histologically or cytologically proved breast cancer * relapse/recurrent brain metastasis progression after brain radiotherapy * presence of brain measurable disease which is defined as at least one brain lesion that can be measured in at least 1 dimension as ³ 20 mm with magnetic resonance image (mri) * prior chemotherapy or hormone therapy for metastatic breast cancer is allowed * performance status of ecog 0, 1, 2 * with normal left ventricular ejection fraction and normal ventricular contractility * age 21 years or older * life expectancy equal or longer than 3 months * ability to understand and the willingness to sign a written informed consent document exclusion criteria: * prior anthracycline-containing chemotherapy with cumulative dose exceed 400mg/m2 doxorubicin or 750 mg/m2 epirubicin * surgery , radiotherapy, hormonal therapy or chemotherapy within 4 weeks prior to entering the study * prior liposomal doxorubicin treatment * concurrent chemotherapy, radiotherapy, hormonal therapy, or other investigational drug except non-disease related conditions (e.g. insulin for diabetes) during study period * other malignancy with exception of curative treated non-melanoma skin cancer or cervical carcinoma in situ within 5 years prior to entering the study * brain metastases defined as meninges metastases * presence of serious concomitant illness which might be aggravated by study medication: * uncontrolled infection (active serious infections that are not controlled by antibiotics) * active cardiac disease e.g. decompensate myocardial infarction within the 6-month period preceding entry into the study. * history of ventricular arrhythmia or congestive heart failure. * presence of abnormal left ventricular ejection fraction * hematopoietic function as defined below: * hemoglobin\<10g/dl * anc\< 1,500/ul * platelets\<100,000/ul * organ function as defined below: * total bilirubin \>1.5 × uln * alt / ast\>3 × uln (\>5.0 x uln if hepatic metastasis) * creatinine \>1.5 × uln * mental status is not fit for clinical trial * pregnant or breast feeding women, or women of child-bearing potential unless using a reliable and appropriate contraceptive method

Keywords: breast cancer brain metastatsis lipo-dox
a feasibility trial and protocol for remote cognitive training developed for use in a cognitively healthy adult population during the covid-19 pandemic

Conditions: Cognition Disorders in Old Age

Summary: the covid-19 pandemic has created a shift in the use of at-home spaces for work, play and research. in the current study, the feasibility of implementing an at-home cognitive training tool called neurotrackerx, an anaglyph version of the three-dimensional multiple object tracking (3d-mot) software neurotracker was examined, and with the intent of developing an effective protocol and determining the suitability of this tool for research purposes .

the work looks at the feasibility of using a newly developed anaglyph 3d cognitive training tool called neurotrackerx in research with adult participants. the work looks to validate an at-home program by comparing participants who complete an online version of neurotracker (neurotrackerx) with a group of individuals who completed the classically used in-lab version (neurotracker). due to covid-19, many laboratories forced to transition to remote-based studies, and the purpose of the work is to validate the remote-based protocol. twenty cognitively healthy adults (10 male; 10 female) were recruited to engage in this at-home program. the results of these individuals will be compared with results from a group of cognitively healthy adults who had previously engaged in the in-lab version of the program prior to the pandemic.

Eligibility criteria:
inclusion criteria: * inclusion criteria for both groups included being aged 50 years and older and to have either normal or corrected vision. exclusion criteria: * exclusion criteria included the presence of any major neurocognitive disorder or the presence of visual deficits that impeded one's ability to complete the 3d task.

Keywords: 3-dimensional multiple object tracking cognitive training neurotracker
the effect of a chatgpt-supported online group-guided self-help program on uncontrolled and emotional eating behaviors and body image in overweight and obese woman nurses

Conditions: Overweight (BMI &gt; 25); Obesity and Overweight; Emotional Eating; Binge Eating

Summary: nurses with overweight and female gender characteristics often experience disruptions in their eating behaviors due to stressful working conditions. these disruptions can lead to physical and psychosocial problems (nicholls et al., 2017). studies have shown that guided self-help programs, based on cognitive behavioral therapy interventions, are effective in addressing uncontrolled and emotional eating behaviors (carrard et al., 2011; cachelin et al., 2015). however, the use of supportive tools to assist the facilitator in group-based interventions of these evidence-based self-help programs and their impact on individual recovery processes remain unexplored. additionally, no studies have been found investigating the application of these ai-supported guided self-help programs among female nurses, who are frequently exposed to stress and at high risk of obesity. given the demanding workloads of nurses, cost-effective and easily accessible online programs have been found to promote recovery (jenkins et al., 2021). therefore, it is essential to test this ai-supported program in an online group format with overweight and obese woman nurses. the aim of this study is to evaluate the effect of a chatgpt-supported online group-guided self-help program on uncontrolled and emotional eating behaviors and body image in overweight and obese woman nurses through a randomized controlled trial. participants will be recruited via an announcement shared on social media platforms (instagram). nurses who respond to the announcement will be asked to complete a survey through google forms. those randomly assigned to the intervention group will participate in online group sessions conducted via google meets. pre- and post-test data will be collected using google forms.


Eligibility criteria:
inclusion criteria: * hold at least a bachelor's degree in nursing from a nursing school. * work as a nurse in an institution. * be a woman. * have a bmi (body mass index) greater than 24.99. * not have a hearing impairment that would prevent them from understanding and completing verbal instructions. * have access to a smartphone or computer with a camera. * agree to participate in the study. * score 50 or higher on the emotional eating and external eating subscales of the dutch eating behavior questionnaire (debq). exclusion criteria: * refusal to participate in the study. * diagnosis of chronic diseases such as diabetes, hyperlipidemia, hypertension, or hyperthyroidism.

Keywords: chatgpt self help group online
use of herbal medicine in internal medicine wards

Conditions: Herb-drug Interactions

Summary: herbs are physiologically active substances which can significantly affect the outcome of medical treatment, either by inhibiting or promoting drug disposition or through additive and synergistic effects when used in conjunction with conventional medications. herb-drug interactions are potentially dangerous, and may be difficult to predict since regulation of the preparations is often lacking, and patients most often do not report the use of these products to their physicians. the risk for toxic effects and adverse interactions increases among high-risk groups, such as the elderly or patients with renal or hepatic disease. the purpose of this study is to study the prevalence of use of herbal medicine among patients hospitalized in the internal medicine department of an israeli hospital, as well as examine the effect of herbal remedies on patient health, either beneficial or harmful. for this purpose, a questionnaire evaluating demographic data, medical history (both current and past), use of and attitudes towards herbal medicine will be administered to patients in the department of internal medicine at the shaare zedek medical center in israel. the beck depression questionnaire will be used as well.


Eligibility criteria:
inclusion criteria: * patients of either gender * age 18 years and older exclusion criteria: * neurological deficit or other medical condition precluding responding to the questionnaires.

Keywords: internal medicine herbal medicine prevalence attitudes herb-drug interaction
juntos/together program to build confidence for complex care tasks among latino family caregivers

Conditions: Dementia Caregivers

Summary: the overall goal of this study is to culturally adapt and test the effectiveness of learning skills together (lst) in improving self-efficacy among latino family caregivers. to address this overall goal, the study team propose the following aims: i) culturally adapt the lst intervention for latino caregivers using a community-engaged approach; and ii) examine the effect of the lst intervention on latino caregiver self-efficacy, depression, and well-being using a randomized wait-list control group.

the study team will use a randomized wait-list control group design with blinded outcomes assessment to examine the effectiveness of lst-lc on caregiver confidence and self-efficacy in performing complex care tasks. this design has the advantage of making enrollment more feasible as participants may find the intervention highly desirable and will eventually receive it. yet, the design provides a randomized comparison with a non-intervention control group. participants will be individually randomized 1:1 to an immediate intervention group (ig) and a wait-list (delayed) control group (wlc).

Eligibility criteria:
inclusion criteria: 1. a family member to an individual living with ad/adrd (alzheimers disease/alzheimers disease and related dementias) who has received a diagnosis from a physician, 2. aged 18 years or older, 3. providing assistance with at least two instrumental activities of daily living or one activity of daily living, 4. providing care to a person with dementia in mid-stage as defined by a score between 4 and 6 on the global deterioration scale (gds), and 5. not paid to provide care exclusion criteria: 1. are unable to read and speak english or spanish, 2. previously participated in lst, and/or 3. have plans to place the care recipient in a skilled nursing facility within the next 6 months (i.e., study duration). 4. participants must have a patient health questionnaire (phq-9) score of less than 15, the threshold for moderately severe depression 5. participants with severe depression

Keywords: latino caregivers
study to evaluate nilotinib in adult patients with imatinib-resistant or imatinib-intolerant chronic myelogenous leukemia (cml), or relapse/refractory ph+ acute lymphoblastic leukemia (all) (extension study)

Conditions: Chronic Myelogenous Leukemia; Acute Lymphoblastic Leukemia

Summary: this study will investigate if nilotinib provides an improved safety and efficacy profile over that seen in patients receiving imatinib.


Eligibility criteria:
inclusion criteria: * patients who complete camn107a1101 and obtained informed concent by document exclusion criteria: * none

Keywords: chronic myelogenous leukemia cml acute lymphoblastic leukemia philadelphia chromosome positive, ph+ all acute lymphoblastic leukemia (philadelphia chromosome positive)
the evaluation of a nasal mask for the treatment of obstructive sleep apnea (osa)

Conditions: Sleep Disordered Breathing; Obstructive Sleep Apnea

Summary: this investigation is designed to evaluate the performance (leak and comfort) as well as the participant's overall acceptance of the trial nasal mask amongst obstructive sleep apnea (osa) participants. an important factor in this investigation will be the testing of two different seal sizes on the participants (medium and large size). a total number of 12 participants who currently use nasal or nasal pillow masks will be recruited for the trial. participants have been selected based on their anthropometric measurements collected in previous trials (cia-103). participants from previous nz trials may be recruited into this trial with their consent. all the participants will be recruited from the fisher \& paykel healthcare database of subjects with osa (ethics reference nty/08/06/064), auckland district health board (adhb) and new zealand respiratory and sleep institute (nzrsi). participants will use the trial mask in home for a period of 7 ± 3 days and also 1 overnight polysomnography session at the fisher \& paykel healthcare sleep lab. baseline data will be collected from the participant during the first visit, 7 days of cpap usage data will be downloaded and stored for analysis. the participant will use the trial device on their usual continuous or auto positive airway pressure (cpap/apap) setting and device for the duration of the trial.


Eligibility criteria:
inclusion criteria: * adult (18+ years of age) * able to give consent * apnea hypopnea index (ahi) ≥ 5 on diagnostic night * prescribed a continuous positive airway pressure (cpap) device after successful osa diagnosis * existing nasal or nasal pillow mask user exclusion criteria: * inability to give consent * patients who are in a coma or a decreased level of consciousness. * anatomical or physiological conditions making apap therapy inappropriate (e.g. unconsolidated facial structure) * commercial drivers who are investigated by new zealand transport agency (nzta) * current diagnosis of co2 retention * pregnant or may think they are pregnant.
effect of dupilumab on nasal epithelial barrier function in patients with crswnp

Conditions: Chronic Rhinosinusitis With Nasal Polyps; Chronic Rhinosinusitis Without Nasal Polyps

Summary: the investigators aim to investigate two major so far unresolved topics in crswnp research: (1) thorough functional and molecular characterisation of barrier function in patients suffering from crssnp and crswnp and (2) effect of dupilumab treatment on barrier function in polyp patients. this will be achieved in patient-derived samples by employing measurement of barrier function in primary cell cultures in combination with a mass cytometry based imaging approach, transcriptomic analysis as well as cytokine and microbiome data of individual patients.

primary objective 1: characterization of differences in barrier function of the nasal epithelium in patients suffering from crssnp, crswnp with and without asthma or n-erd (in absence of therapy with monoclonal antibodies). t primary objective 2: effect of dupilumab treatment on barrier function of the nasal epithelium in patients suffering from crswnp with and without asthma or n-erd.

Eligibility criteria:
inclusion criteria: * 18-99 years of age * willingness to participate in the study * suffer from chronic rhinosinusitis defined as in epos 2020 criteria, see main text * group 1 (n=20, crssnp): absence of nasal polyps * group 2 (n=60, crswnp): presence of nasal polyps as confirmed by endoscopy or ct and planned therapy with dupilumab * presence or absence of non-steroidal anti-inflammatory drug (nsaid)-exacerbated respiratory disease (n-erd) * patients with a history of treatment with monoclonal antibodies will only be included if at least a washout period of 6 months has passed exclusion criteria: * pregnancy (as determined by ß-hcg test) or breast feeding * patients with severe anatomic variations or deviations that do not allow access to all areas in the nasal cavity * patients with cystic fibrosis or primary ciliary dyskinesia * patients with permanent immunosuppression * a mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study * patients with clinically meaningful comorbidity as determined by the evaluating committee * patients with a history of exacerbation of chronic rhinosinusitis 4 weeks prior to the screening visit * intake of a burst of systemic corticosteroids for the treatment of crs 4 weeks prior to the screening visit
a study to assess bms-986207 in combination with nivolumab and ipilimumab as first-line treatment for participants with stage iv non-small cell lung cancer

Conditions: Non-Small Cell Lung Cancer

Summary: the purpose of this study is to determine the safety and efficacy of bms-986207 in combination with nivolumab and ipilimumab as first-line treatment for participants with stage iv non-small cell lung cancer (nsclc).


Eligibility criteria:
inclusion criteria: * histologically confirmed metastatic 1l stage iv non-small cell lung cancer (nsclc) of squamous or nonsquamous histology * no prior systemic anti-cancer treatment given as primary therapy for advanced or metastatic nsclc * measurable disease as per response evaluation criteria in solid tumors (recist) v1.1 * eastern cooperative oncology group (ecog) performance status 0-1 * a formalin-fixed, paraffin-embedded (ffpe) tumor tissue block or a minimum of 20 unstained slides of tumor tissue obtained during screening or prior to enrollment * life expectancy of at least 3 months at the time of first dose exclusion criteria: * participants with epidermal growth factor receptor (egfr), anaplastic lymphoma kinase (alk), or c-ros oncogene 1 (ros-1) mutations which are sensitive to available targeted inhibitor therapy. participants with nonsquamous histology and unknown egfr, alk, or ros-1 status are also excluded * participants with known b-rapidly accelerated fibrosarcoma proto-oncogene (braf) v600e mutations that are sensitive to available targeted inhibitor therapy. participants with unknown or indeterminate braf mutation status are eligible. * untreated central nervous system metastases * leptomeningeal metastases (carcinomatous meningitis) * concurrent malignancy requiring treatment * active, known, or suspected autoimmune disease * interstitial lung disease * uncontrolled or significant cardiovascular disease other protocol-defined inclusion/exclusion criteria apply

Keywords: non-small cell lung cancer nsclc bms-986207 nivolumab opdivo ipilimumab yervoy
impact of implementation of an enhanced recovery after surgery program in laparoscopic roux-en-y gastric bypass

Conditions: Postoperative Pain

Summary: a prospective randomized study of patients undergoing roux-en-y gastric bypass will be randomized in 2 groups: those following an eras program and those ones following a standard protocol. postoperative pain 24 hours after surgery and hospital stay will be assessed.

a prospective randomized study of patients undergoing roux-en-y gastric bypass will be randomized in 2 groups: those following an enhanced recovery after surgery (eras) program and those ones following a standard protocol. the eras program implies early liquids oral intake, early deambulation and multimodal analgesia (port sites infiltration with bupivacain 0.5% associated with intravenous analgesia). postoperative pain 24 hours after surgery, as measured by visual analogic scale, and hospital stay will be assessed.

Eligibility criteria:
inclusion criteria: * body mass index (bmi) \>40 kg/m2 * bmi \>35 kg/m2 with obesity-associated comorbidities exclusion criteria: * patients undergoing other bariatric procedures * patients undergoing bariatric revisional surgery
the relationship of ultrasonographic measurements with sarcopenia in stroke

Conditions: Hemiplegia

Summary: introduction:the aim of this study was to show the relationship of distal femoral cartilage and quadriceps thicknesses with functional status and presence of sarcopenia in ambulatory stroke patients with voluntary movement. materials and method: forty-eight patients who were diagnosed with stroke due to cerebrovascular disease, had started voluntary movement, and had a motor recovery of 3 or above according to brunnstrom's staging were included in this cross-sectional study.

forty-eight patients who were diagnosed with stroke due to cerebrovascular disease, had started voluntary movement, and had a motor recovery of 3 or above according to brunnstrom's staging were included in this cross-sectional study. bilateral distal femoral cartilage thickness and quadriceps femoris (rectus femoris+vastus intermedius) thickness were measured by ultrasonography. in addition, a simple questionnaire to rapidly diagnose sarcopenia (sarc-f questionnaire), hand grip strength, muscle mass measurement with dual energy x-ray absorptiometry (dxa), short physical performance battery (kfpb) tests were performed and the presence of sarcopenia the european working group on sarcopenia in older people-2 (ewgsop- 2) were evaluated according to the criteria. patients' functional independence scale (fim), functional ambulation scale (fas), barthel index and modified ashworth scale (mas) were evaluated.

Eligibility criteria:
inclusion criteria: * between 18 and 90 years old * presence of a history of ischemic or hemorrhagic stroke (based on ct and/or magnetic resonance imaging (mri) report) * brunnstrom hemiplegia recovery staging, stage 3≥ exclusion criteria: * history of recurrent cerebrovascular accident * more than 2 years have passed since the history of cerebrovascular accident * inflammatory arthritis or any other rheumatic disease * history of trauma to the knee (cruciate ligament or meniscus trauma) * previous knee surgery * pre-stroke neurological gait disorder * lower extremity amputation * knee joint contracture

Keywords: distal femoral cartilage thickness quadriceps muscle thickness functionality sarcopenia hemiplegia